Market Report: Berenberg says Shire Pharmaceuticals is worthy of investors' attention


Click to follow

Forget AbbVie, Shire Pharmaceuticals is now a proper business in its own right. So say analysts at Berenberg, who suggest the company’s rare disease drug pipeline alone is worthy of the attention of investors.

Much of the interest has surrounded a possible takeover, with the US pharma giant walking away from a possible £32bn deal last year after opposition to “tax inversion” deals. But Berenberg’s number crunchers suggest buying shares in Shire, up 60p at 5,500p, for reasons besides a possible buyout.

“We believe that Shire has successfully refocused as a standalone business following the collapse of the planned AbbVie acquisition in October last year, and is transforming itself into a true specialty pharma company with a robust rare disease pipeline,” its analysts said.

The broker has a buy recommendation and a 6,300p target price.

Greece’s Parliament gave the bailout deal a reluctant thumbs-up, helping the FTSE 100 up 42.7 points to 6,796.45.

There was more good news as the European Central Bank extended its funding for Greek banks by €900m (£625m) for another week.

The supermarket groups shrugged off the findings  of the competition watchdog, which said confusing promotions  mean they “could be in breach of consumer law”. Tesco edged up 0.55p to 217.65p, Morrisons rose 0.6p to 181.5p, while Sainsbury’s gained 1.3p to 267.9p.

Israeli billionaire Teddy Sagi’s Playtech, up 5p at 886.5p, sealed the much talked-about takeover of Plus500, up 0.75p at 389p.

Odey Asset Management, which had 25.5 per cent of the voting rights, opted not to block the deal despite initially claiming the 400p-a-share bid undervalued the company. The vote required just 50.1 per cent shareholder approval.

The AIM-listed natural resources minnow Metal Tiger, up 2.6 per cent to 1p, unveiled early-stage results from its tungsten project in Spain. Another of chief executive Cameron Parry’s business ventures announced plans for a float. Coinsilium, which invests in the technology that powers bitcoins, is gearing up for an AIM listing in August.